NRG GY023

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian

Status:

Closed

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

NCT#04739800

GY023 is closed to accrual, effective February 2, 2023.